IVF treatment should not be postponed for patients with high basal FSH concentrations
Abstract
This study determined the influence of inter-cycle variation of basal FSH concentrations on IVF treatment results, in patients with a history of high basal FSH. Patients underwent at least two IVF cycles, one with basal serum FSH ⩾10
IU/l and the other at least 3
IU/l lower (interval between cycles being <1
year when the second cycle had the elevated FSH). A subanalysis was performed in patients with exceptionally large differences in values (⩾16
IU/l and ⩽12
IU/l). IVF outcomes were compared according to basal FSH concentrations in two consecutive cycles. Seventy-six patients met the inclusion criteria. Mean basal serum FSH were 15.0
±
3.6
IU/l in the ‘high FSH’ group (range 12–24
IU/l) and 9.0
±
3.0
IU/l in the ‘low FSH’ group (range 5–14
IU/l). Patient age, oestradiol at HCG administration, number of collected oocytes, fertilization and clinical pregnancy rates were similar for all cycles compared. Analysis of the subgroup with exceptionally large differences of basal FSH concentration yielded similar results. Neither high nor low basal serum FSH values were associated with IVF outcome in patients with reduced ovarian reserve and previously determined high basal FSH concentrations. Ovarian stimulation need not be delayed until FSH declines.
Keywords: FSH, IVF, pregnancy rate, reduced ovarian reserve
To access this article, please choose from the options below
Dr Ettie Maman is a senior physician in the IVF unit, Department of Obstetric and Gynecology, Sheba Medical Center, Tel Aviv University, Israel. She graduated from Ben Gurion University, School of Medicine in Beer Sheba, Israel, in 1998. She completed her residency in Obstetrics and Gynecology at the Department of Obstetric and Gynecology, Sheba Medical Center. She worked as a research fellow at the Samuel Lunenfeld Research Institute, Mt Sinai Hospital, Toronto, Ontario, Canada. She joined the Sheba Medical Center IVF programme in 2006 and her research interests are related to infertility, in vitro maturation and stem cells.
PII: S1472-6483(10)00337-8
doi:10.1016/j.rbmo.2010.05.013
© 2010 Reproductive Healthcare Ltd. Published by Elsevier Inc All rights reserved.
